Introduction: The prognostic role of BRCA1 associated protein-1 (BAP1) expression in malignant pleural mesothelioma (MPM) is a matter of debate. We aimed to clarify whether MPM patients with loss of BAP1 expression have better overall survival (OS) compared to BAP1 positive patients.
Methods: [ BRCA1 associated protein-1 (BAP1) ] immunohistochemical staining of tumor samples from 60 [ malignant pleural mesothelioma (MPM) ] patients treated at our institution with first-line chemotherapy was evaluated. A systematic literature search was also performed. Only cohort studies that investigated BAP1 by immunohistochemistry (IHC) and reported hazard ratio (HR) values for OS obtained through multivariate analysis (or adjusted for histotype) were considered. A dataset comprising 638 MPM patients was added to our cohort and included in the meta-analysis.
Conclusions: [ BRCA1 associated protein-1 (BAP1) ] expression is not an independent prognostic factor for [ malignant pleural mesothelioma (MPM) ] patients and it should not be considered without taking into account tumor histotype. Future studies should investigate its predictive role in patients treated with new emerging therapies such as immunotherapy.
Asbestos-Mesothelioma Case Evaluation
Free. Confidential. No Obligation.